| --- | --- | --- | |---------------------------|-------|-------| | | | | | | | | | Ironwood Q4 and Full Year | | | | | | | | | | | | 2021 Investor Update | | | | February 17, 2022 | | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute well against our strategic priorities; the Company's strategy, business, fi ...

Leading in GI through Growth and Innovation J.P. Morgan Healthcare Conference January 12, 2022 PRESENTED BY Tom McCourt, CEO Ironwood Pharmaceuticals, Inc. Safe Harbor Statement 2 This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing LINZESS® (linac ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2021 Results Conference Call November 4, 2021 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Jason Rickard - Chief Operating Officer Conference Call Participants Hannah Adeoye - JPMorgan David Lebowitz - Morgan Stanley Tim Chiang - Northland Capital Operator Good morning. My name is Rob, and I will be your conference operator today. At this time, I would ...

| --- | --- | |------------------|-------| | | | | | | | | | | | | | | | | Ironwood Q3 2021 | | | | | | Earnings Update | | | November 4, 2021 | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to max ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or oth ...

| --- | --- | |-----------------|-------| | | | | | | | | | | Ironwood 2Q | 2021 | | | | | | | | Earnings Update | | | August 5, 2021 | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing L ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Jason Rickard - Chief Operating Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Hannah Adeoye - JPMorgan Avatar Jones - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Ironwood Pharmaceuticals 2Q 2021 Investor Update Call. At this time, all par ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other ju ...

| --- | --- | |------------------|-------| | | | | | | | | | | Ironwood 1Q 2021 | | | | | | Earnings Update | | Ironwood Introduction Meredith Kaya Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing LINZESS® (linaclotide), b ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Meredith Kaya - VP, IR & Corporate Communications Thomas McCourt - President & Interim CEO Gina Consylman - Principal Accounting Officer, CFO, SVP & Treasurer Michael Shetzline - Chief Medical Officer, SVP & Head, Drug Development Conference Call Participants Jacob Hughes - Wells Fargo Securities Hannah Adeoye - JPMorgan Chase & Co. David Lebowitz - Morgan Stanley Operator Good day, and ...